Description
ResMed: Why Restless Legs Syndrome, Sleep Apnea Testing & Digital Platforms Matter Now!
ResMed, Inc. reported its third quarter results for fiscal year 2026, delivering solid financial and operational performance marked by 11% headline revenue growth and 8% growth on a constant currency basis. The company highlighted a significant 21% increase in non-GAAP earnings per share, supported by operating leverage and margin expansion. Gross margin expanded by 290 basis points year-over-year and 50 basis points sequentially, driven by component cost improvements, manufacturing and logistics efficiencies, as well as favorable product mix and currency effects. These improvements come despite ongoing geopolitical uncertainties and fuel cost pressures, with management expressing confidence in sustaining gross margin expansion through 2030 via a robust pipeline of supply chain productivity initiatives. Revenue growth was broad-based geographically, with device sales increasing 6% globally and masks and other sales growing 12%. The Americas region showed a 9% increase, while Europe, Asia, and other regions grew at 7% constant currency.
